Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PVC

This article was originally published in The Gray Sheet

Executive Summary

Risk assessment of di (2-ethylhexyl) phthalate (DEHP) performed by the Office of Science and Technology in 2000 will help form the basis for the device center's decision on a June 1999 Heath Care Without Harm citizen petition (1"The Gray Sheet" June 28, 1999, p. 12). The petition called for labeling polyvinyl chloride devices with warnings that indicate potential hazards of DEHP leaching from the PVC device and information on FDA-approved alternatives to PVC. The OST risk hazard report is currently being reviewed by the FDA Senior Science Council and could be released to the public as soon as mid-August, staffers indicate

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel